MedTrace Logo

Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer

NCT05369000 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2025-08-01

No results posted yet for this study

Summary

This is a phase 1, first-in-human study to evaluate Safety, Tolerability, PK, PD, Immunogenicity, and Antitumor Activity of LAVA-1207 alone or with low dose interleukin-2 or Pembrolizumab, in patients with therapy refractory metastatic castration resistant prostate cancer.

Conditions

  • Metastatic Castration Resistant Prostate Cancer

Interventions

BIOLOGICAL

LAVA-1207

In part 1 \& part 2 • LAVA-1207 will be administered via intravenous infusion.

BIOLOGICAL

LAVA-1207 plus Pembrolizumab

Pembrolizumab will be administered via intravenous infusion

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials Management · Lava Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-17
Primary Completion
2025-06-18
Completion
2025-06-18
FDA Drug
Yes

Countries

  • United States
  • Netherlands
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05369000 on ClinicalTrials.gov